Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Adult
Aged
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Renal Cell
/ drug therapy
Drug Resistance, Neoplasm
/ drug effects
Female
Follow-Up Studies
Furans
/ administration & dosage
Humans
Kidney Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Prognosis
Pyridines
/ administration & dosage
Pyrimidines
/ administration & dosage
Receptor, Adenosine A2A
/ chemistry
Salvage Therapy
Survival Rate
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
23
08
2019
revised:
15
10
2019
accepted:
07
11
2019
pubmed:
17
11
2019
medline:
13
2
2021
entrez:
17
11
2019
Statut:
ppublish
Résumé
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial with a small-molecule A2AR antagonist. We find that this molecule can safely block adenosine signaling
Identifiants
pubmed: 31732494
pii: 2159-8290.CD-19-0980
doi: 10.1158/2159-8290.CD-19-0980
pmc: PMC6954326
mid: NIHMS1543213
doi:
Substances chimiques
ADORA2A protein, human
0
Antibodies, Monoclonal, Humanized
0
Furans
0
Pyridines
0
Pyrimidines
0
Receptor, Adenosine A2A
0
atezolizumab
52CMI0WC3Y
ciforadenant
8KFO2187CP
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
40-53Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA223484
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA233100
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2019 American Association for Cancer Research.
Références
Lancet Oncol. 2018 Apr;19(4):451-460
pubmed: 29530667
Toxicol Appl Pharmacol. 2017 Jan 1;314:72-81
pubmed: 27899277
Cancer Res. 2014 Dec 15;74(24):7239-49
pubmed: 25341542
Cancer Immunol Res. 2015 May;3(5):506-17
pubmed: 25672397
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nat Rev Cancer. 2013 Dec;13(12):842-57
pubmed: 24226193
Cancer Res. 1997 Jul 1;57(13):2602-5
pubmed: 9205063
JAMA Oncol. 2018 Apr 01;4(4):522-528
pubmed: 29470579
Am J Cancer Res. 2014 Mar 01;4(2):172-81
pubmed: 24660106
Cancer Res. 2018 Feb 15;78(4):1003-1016
pubmed: 29229601
J Immunol Methods. 2012 Jan 31;375(1-2):14-9
pubmed: 21945395
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
J Clin Invest. 2017 Mar 1;127(3):929-941
pubmed: 28165340
J Immunother Cancer. 2018 Nov 6;6(Suppl 1):114
pubmed: 30400835
Blood. 2009 Nov 5;114(19):4099-107
pubmed: 19706884
Cancer Immunol Res. 2018 Oct;6(10):1136-1149
pubmed: 30131376
Clin Cancer Res. 2013 Oct 15;19(20):5626-35
pubmed: 23983257
J Med Chem. 2014 May 8;57(9):3623-50
pubmed: 24164628
Nat Commun. 2013;4:2680
pubmed: 24157944
Sci Transl Med. 2015 Mar 4;7(277):277ra30
pubmed: 25739764
Acta Oncol. 2018 Apr;57(4):498-508
pubmed: 29095068
Cancer Res. 2014 Jul 15;74(14):3652-8
pubmed: 24986517
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Cancer Res. 2006 Aug 1;66(15):7758-65
pubmed: 16885379
J Clin Invest. 2002 Oct;110(7):993-1002
pubmed: 12370277
Sci Transl Med. 2014 May 28;6(238):238ra70
pubmed: 24871131
Nat Immunol. 2017 Dec;18(12):1332-1341
pubmed: 29083399
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14711-6
pubmed: 23964122
Cancer Immunol Res. 2014 Jul;2(7):598-605
pubmed: 24990240
Cancer Immunol Immunother. 2018 Aug;67(8):1271-1284
pubmed: 29923026
Nature. 2001 Dec 20-27;414(6866):916-20
pubmed: 11780065
J Biol Chem. 2010 Mar 5;285(10):7176-86
pubmed: 19858205
Oncoimmunology. 2013 Dec 1;2(12):e26705
pubmed: 24575377
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11091-6
pubmed: 23776241
Cancer Immunol Immunother. 2012 Jun;61(6):917-26
pubmed: 22116345
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
pubmed: 16916931
J Mol Med (Berl). 2014 Dec;92(12):1283-92
pubmed: 25120128
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Immunol Res. 2006;36(1-3):91-9
pubmed: 17337770
Am J Physiol. 1989 Apr;256(4 Pt 1):C799-806
pubmed: 2539728
Trends Immunol. 2009 Mar;30(3):102-8
pubmed: 19201652
Cancer Discov. 2018 Sep;8(9):1156-1175
pubmed: 30012853
Blood. 2008 Jan 1;111(1):251-9
pubmed: 17909080
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
J Immunol. 2018 Jul 15;201(2):782-791
pubmed: 29802128
Cell Signal. 2013 Sep;25(9):1913-23
pubmed: 23712033